These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 19875477)

  • 1. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes.
    Zinman B; Haffner SM; Herman WH; Holman RR; Lachin JM; Kravitz BG; Paul G; Jones NP; Aftring RP; Viberti G; Kahn SE;
    J Clin Endocrinol Metab; 2010 Jan; 95(1):134-42. PubMed ID: 19875477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systems biology approach to identify effective cocktail drugs.
    Wu Z; Zhao XM; Chen L
    BMC Syst Biol; 2010 Sep; 4 Suppl 2(Suppl 2):S7. PubMed ID: 20840734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The effect of hypoglycemic drugs on bone metabolism in type 2 diabetes mellitus].
    Chen YQ; Zhang XZ
    Zhonghua Nei Ke Za Zhi; 2024 Jun; 63(6):626-632. PubMed ID: 38825934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin.
    Ljunggren Ö; Bolinder J; Johansson L; Wilding J; Langkilde AM; Sjöström CD; Sugg J; Parikh S
    Diabetes Obes Metab; 2012 Nov; 14(11):990-9. PubMed ID: 22651373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus.
    Bilezikian JP; Josse RG; Eastell R; Lewiecki EM; Miller CG; Wooddell M; Northcutt AR; Kravitz BG; Paul G; Cobitz AR; Nino AJ; Fitzpatrick LA
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1519-28. PubMed ID: 23450056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin.
    Bilezikian JP; Watts NB; Usiskin K; Polidori D; Fung A; Sullivan D; Rosenthal N
    J Clin Endocrinol Metab; 2016 Jan; 101(1):44-51. PubMed ID: 26580234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus.
    van Lierop AH; Hamdy NA; van der Meer RW; Jonker JT; Lamb HJ; Rijzewijk LJ; Diamant M; Romijn JA; Smit JW; Papapoulos SE
    Eur J Endocrinol; 2012 Apr; 166(4):711-6. PubMed ID: 22267280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of fractures and diabetes medications: a nationwide cohort study.
    Choi HJ; Park C; Lee YK; Ha YC; Jang S; Shin CS
    Osteoporos Int; 2016 Sep; 27(9):2709-2715. PubMed ID: 27080708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effects of Pioglitazone on Bone Formation and Resorption Markers in Type 2 Diabetes Mellitus.
    Mori H; Okada Y; Tanaka Y
    Intern Med; 2017; 56(11):1301-1306. PubMed ID: 28566590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus.
    Watts NB; Bilezikian JP; Usiskin K; Edwards R; Desai M; Law G; Meininger G
    J Clin Endocrinol Metab; 2016 Jan; 101(1):157-66. PubMed ID: 26580237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the anti-osteoporotic effects of metformin and sitagliptin in postmenopausal diabetic women.
    Hegazy SK
    J Bone Miner Metab; 2015 Mar; 33(2):207-12. PubMed ID: 24633493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus.
    Rubin MR; Manavalan JS; Agarwal S; McMahon DJ; Nino A; Fitzpatrick LA; Bilezikian JP
    J Clin Endocrinol Metab; 2014 Oct; 99(10):E1933-42. PubMed ID: 24905061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of metformin versus placebo in combination with insulin analogues on bone mineral density and trabecular bone score in patients with type 2 diabetes mellitus: a randomized placebo-controlled trial.
    Nordklint AK; Almdal TP; Vestergaard P; Lundby-Christensen L; Boesgaard TW; Breum L; Gade-Rasmussen B; Sneppen SB; Gluud C; Hemmingsen B; Jensen T; Krarup T; Madsbad S; Mathiesen ER; Perrild H; Tarnow L; Thorsteinsson B; Vestergaard H; Lund SS; Eiken P
    Osteoporos Int; 2018 Nov; 29(11):2517-2526. PubMed ID: 30027438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world antidiabetic drug use and fracture risk in 12,277 patients with type 2 diabetes mellitus: a nested case-control study.
    Losada E; Soldevila B; Ali MS; Martínez-Laguna D; Nogués X; Puig-Domingo M; Díez-Pérez A; Mauricio D; Prieto-Alhambra D
    Osteoporos Int; 2018 Sep; 29(9):2079-2086. PubMed ID: 29860664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of metformin, rosiglitazone and insulin on bone metabolism in patients with type 2 diabetes.
    Stage TB; Christensen MH; Jørgensen NR; Beck-Nielsen H; Brøsen K; Gram J; Frost M
    Bone; 2018 Jul; 112():35-41. PubMed ID: 29654849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin; an old antidiabetic drug with new potentials in bone disorders.
    Bahrambeigi S; Yousefi B; Rahimi M; Shafiei-Irannejad V
    Biomed Pharmacother; 2019 Jan; 109():1593-1601. PubMed ID: 30551413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews.
    Pelletier R; Ng K; Alkabbani W; Labib Y; Mourad N; Gamble JM
    Ther Adv Drug Saf; 2021; 12():2042098621989134. PubMed ID: 33552467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between combined treatment with SGLT2 inhibitors and metformin for type 2 diabetes mellitus on fracture risk: a meta-analysis of randomized controlled trials.
    Qian BB; Chen Q; Li L; Yan CF
    Osteoporos Int; 2020 Dec; 31(12):2313-2320. PubMed ID: 32780153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin use and risk of fracture: a systematic review and meta-analysis of observational studies.
    Salari-Moghaddam A; Sadeghi O; Keshteli AH; Larijani B; Esmaillzadeh A
    Osteoporos Int; 2019 Jun; 30(6):1167-1173. PubMed ID: 30927035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of diabetes and diabetes medications on bone health.
    Gilbert MP; Pratley RE
    Endocr Rev; 2015 Apr; 36(2):194-213. PubMed ID: 25738213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.